BCSCDB: Biomarkers of Cancer Stem Cells Database
Number of entries related to BxPC-3 cell line is 113
| GENE | HGNC_ID | MARKER_TYPE | CANCER_TYPE | HISTOLOGICAL_TYPE | CELL_LINE | CSC_ENRICHMENT | METHOD | EXPRESSION_LEVEL | CONFIDENCE_SCORING | GLOBAL_SCORING | PUBMED_ID |
|---|---|---|---|---|---|---|---|---|---|---|---|
| CD44 | 1681 | LTM | Pancreatic Cancer | Adenocarcinoma | BxPC-3 | NA | IF staining followed by Western Blotting | NA | 0.52 | 1 | 31388092 |
| CD44 | 1681 | LTM | Pancreatic Cancer | Adenocarcinoma | BxPC-3 | NA | SFA followed by RT-PCR and Western Blotting | NA | 0.52 | 1 | 30802827 |
| CD44 | 1681 | LTM | Pancreatic Cancer | Adenocarcinoma | BxPC-3 | NA | SFA followed by RT-PCR and Western Blotting | NA | 0.52 | 1 | 30802827 |
| CD44 | 1681 | LTM | Pancreatic Cancer | Adenocarcinoma | BxPC-3 | NA | Western Blotting and SFA followed by FACs | NA | 0.52 | 1 | 33082357 |
| CD44 | 1681 | LTM | Pancreatic Cancer | Adenocarcinoma | BxPC-3 | NA | CFA and FACs followed by qRT-PCR | NA | 0.52 | 1 | 21826251 |
| CD44 | 1681 | LTM | Pancreatic Cancer | Adenocarcinoma | BxPC-3 | NA | Western Blotting | NA | 0.52 | 1 | 29970519 |
| CD44 | 1681 | LTM | Pancreatic Cancer | Adenocarcinoma | BxPC-3 | NA | SFA followed by IF staining | NA | 0.52 | 1 | 26709750 |
| CD44 | 1681 | LTM | Pancreatic Cancer | Adenocarcinoma | BxPC-3 | Gemcitabine | qRT-PCR | NA | 0.52 | 1 | 26035122 |
| CD44 | 1681 | LTM | Pancreatic Cancer | Adenocarcinoma | BxPC-3 | NA | qRT-PCR | NA | 0.52 | 1 | 26035122 |
| CD44 | 1681 | LTM | Pancreatic Cancer | Adenocarcinoma | BxPC-3 | NA | SFA followed by qRT-PCR | NA | 0.52 | 1 | 29048549 |
| CD44 | 1681 | LTM | Pancreatic Cancer | Adenocarcinoma | BxPC-3 | NA | FACs | NA | 0.52 | 1 | 22948659 |
| CD44 | 1681 | LTM | Pancreatic Cancer | Adenocarcinoma | BxPC-3 | Gemcitabine | FACs | NA | 0.52 | 1 | 31713003 |
| CD44 | 1681 | LTM | Pancreatic Cancer | Adenocarcinoma | BxPC-3 | NA | FACs | NA | 0.52 | 1 | 31713003 |
| CD44 | 1681 | LTM | Pancreatic Cancer | Adenocarcinoma | BxPC-3 | NA | FACs | NA | 0.52 | 1 | 31856088 |
| CD44 | 1681 | LTM | Pancreatic Cancer | Adenocarcinoma | BxPC-3 | NA | FACs and CFA followed by SFA and Tumorigenicity assay | NA | 0.52 | 1 | 23017870 |
| CD44 | 1681 | LTM | Pancreatic Cancer | Adenocarcinoma | BxPC-3 | Gemcitabine | FACs followed by SFA | NA | 0.52 | 1 | 27576197 |
| CD44 | 1681 | LTM | Pancreatic Cancer | Adenocarcinoma | BxPC-3 | NA | FACs followed by SFA | NA | 0.52 | 1 | 27748818 |
| CD44 | 1681 | LTM | Pancreatic Cancer | Adenocarcinoma | BxPC-3 | NA | FACs followed by SFA | NA | 0.52 | 1 | 27748818 |
| CD44 | 1681 | LTM | Pancreatic Cancer | Adenocarcinoma | BxPC-3 | NA | FACs followed by SFA | NA | 0.52 | 1 | 27999190 |
| CD44 | 1681 | LTM | Pancreatic Cancer | Adenocarcinoma | BxPC-3 | NA | FACs followed by SP assay | NA | 0.52 | 1 | 22963768 |
| CD44 | 1681 | LTM | Pancreatic Cancer | Adenocarcinoma | BxPC-3 | NA | SFA followed by FACs | NA | 0.52 | 1 | 30853342 |
| CD44 | 1681 | LTM | Pancreatic Cancer | Adenocarcinoma | BxPC-3 | NA | SFA followed by FACs | NA | 0.52 | 1 | 29719602 |
| CXCR4 | 2561 | LTM | Pancreatic Cancer | Adenocarcinoma | BxPC-3 | NA | IF staining followed by Western Blotting | NA | 0.52 | 0.0498 | 31388092 |
| CXCR4 | 2561 | LTM | Pancreatic Cancer | Adenocarcinoma | BxPC-3 | NA | CFA and FACs followed by qRT-PCR | NA | 0.52 | 0.0498 | 21826251 |
| CXCR4 | 2561 | LTM | Pancreatic Cancer | Adenocarcinoma | BxPC-3 | NA | SFA followed by Western Blotting | NA | 0.52 | 0.0498 | 30853342 |
| CXCR4 | 2561 | LTM | Pancreatic Cancer | Adenocarcinoma | BxPC-3 | NA | FACs followed by Tumorigenicity assay | NA | 0.52 | 0.0498 | 23338123 |
| EPCAM | 11529 | LTM | Pancreatic Cancer | Adenocarcinoma | BxPC-3 | NA | IF staining followed by Western Blotting | NA | 0.52 | 0.211 | 31388092 |
| EPCAM | 11529 | LTM | Pancreatic Cancer | Adenocarcinoma | BxPC-3 | NA | SFA followed by IF staining | NA | 0.52 | 0.211 | 26709750 |
| EPCAM | 11529 | LTM | Pancreatic Cancer | Adenocarcinoma | BxPC-3 | NA | FACs | NA | 0.52 | 0.211 | 22948659 |
| EPCAM | 11529 | LTM | Pancreatic Cancer | Adenocarcinoma | BxPC-3 | NA | FACs followed by SFA | NA | 0.52 | 0.211 | 27999190 |
| EPCAM | 11529 | LTM | Pancreatic Cancer | Adenocarcinoma | BxPC-3 | NA | FACs followed by SP assay | NA | 0.52 | 0.211 | 22963768 |
| EPCAM | 11529 | LTM | Pancreatic Cancer | Adenocarcinoma | BxPC-3 | NA | SFA followed by FACs | NA | 0.52 | 0.211 | 30853342 |
| EPCAM | 11529 | LTM | Pancreatic Cancer | Adenocarcinoma | BxPC-3 | NA | SFA followed by FACs | NA | 0.52 | 0.211 | 29719602 |
| ALDH1A1 | 402 | LTM | Pancreatic Cancer | Adenocarcinoma | BxPC-3 | NA | SFA followed by RT-PCR and Western Blotting | NA | 0.48 | 0.684 | 30802827 |
| ALDH1A1 | 402 | LTM | Pancreatic Cancer | Adenocarcinoma | BxPC-3 | NA | SFA followed by RT-PCR and Western Blotting | NA | 0.48 | 0.684 | 30802827 |
| ALDH1A1 | 402 | LTM | Pancreatic Cancer | Adenocarcinoma | BxPC-3 | NA | SFA followed by Western Blotting | NA | 0.48 | 0.684 | 30853342 |
| ALDH1A1 | 402 | LTM | Pancreatic Cancer | Adenocarcinoma | BxPC-3 | NA | qRT-PCR | NA | 0.48 | 0.684 | 26035122 |
| ALDH1A1 | 402 | LTM | Pancreatic Cancer | Adenocarcinoma | BxPC-3 | NA | SFA followed by qRT-PCR | NA | 0.48 | 0.684 | 29048549 |
| ALDH1A1 | 402 | LTM | Pancreatic Cancer | Adenocarcinoma | BxPC-3 | NA | ALDEFLUOR assay followed by CFA | NA | 0.48 | 0.684 | 32550888 |
| ALDH1A1 | 402 | LTM | Pancreatic Cancer | Adenocarcinoma | BxPC-3 | NA | ALDEFLUOR assay | NA | 0.48 | 0.684 | 30747824 |
| ALDH1A1 | 402 | LTM | Pancreatic Cancer | Adenocarcinoma | BxPC-3 | NA | ALDEFLUOR assay | NA | 0.48 | 0.684 | 31388092 |
| ALDH1A1 | 402 | LTM | Pancreatic Cancer | Adenocarcinoma | BxPC-3 | NA | ALDEFLUOR assay followed by SFA | NA | 0.48 | 0.684 | 27748818 |
| ALDH1A1 | 402 | LTM | Pancreatic Cancer | Adenocarcinoma | BxPC-3 | NA | FACs followed by SFA | NA | 0.48 | 0.684 | 27748818 |
| ALDH1A1 | 402 | LTM | Pancreatic Cancer | Adenocarcinoma | BxPC-3 | NA | FACs followed by SFA | NA | 0.48 | 0.684 | 27999190 |
| BMI1 | 1066 | LTM | Pancreatic Cancer | Adenocarcinoma | BxPC-3 | Gemcitabine | qRT-PCR and Western Blotting followed by SFA | NA | 0.48 | 0.1135 | 27576197 |
| BMI1 | 1066 | LTM | Pancreatic Cancer | Adenocarcinoma | BxPC-3 | NA | Western Blotting | NA | 0.48 | 0.1135 | 23437065 |
| CD24 | 1645 | LTM | Pancreatic Cancer | Adenocarcinoma | BxPC-3 | NA | SFA followed by RT-PCR and Western Blotting | NA | 0.48 | 0.456 | 30802827 |
| CD24 | 1645 | LTM | Pancreatic Cancer | Adenocarcinoma | BxPC-3 | NA | SFA followed by RT-PCR and Western Blotting | NA | 0.48 | 0.456 | 30802827 |
| CD24 | 1645 | LTM | Pancreatic Cancer | Adenocarcinoma | BxPC-3 | NA | CFA and FACs followed by qRT-PCR | NA | 0.48 | 0.456 | 21826251 |
| CD24 | 1645 | LTM | Pancreatic Cancer | Adenocarcinoma | BxPC-3 | NA | SFA followed by IF staining | NA | 0.48 | 0.456 | 26709750 |
| CD24 | 1645 | LTM | Pancreatic Cancer | Adenocarcinoma | BxPC-3 | NA | qRT-PCR | NA | 0.48 | 0.456 | 26035122 |
| CD24 | 1645 | LTM | Pancreatic Cancer | Adenocarcinoma | BxPC-3 | NA | FACs | NA | 0.48 | 0.456 | 22948659 |
| CD24 | 1645 | LTM | Pancreatic Cancer | Adenocarcinoma | BxPC-3 | NA | FACs | NA | 0.48 | 0.456 | 31856088 |
| CD24 | 1645 | LTM | Pancreatic Cancer | Adenocarcinoma | BxPC-3 | NA | FACs and CFA followed by SFA and Tumorigenicity assay | NA | 0.48 | 0.456 | 23017870 |
| CD24 | 1645 | LTM | Pancreatic Cancer | Adenocarcinoma | BxPC-3 | NA | FACs followed by SFA | NA | 0.48 | 0.456 | 27748818 |
| CD24 | 1645 | LTM | Pancreatic Cancer | Adenocarcinoma | BxPC-3 | NA | FACs followed by SFA | NA | 0.48 | 0.456 | 27748818 |
| CD24 | 1645 | LTM | Pancreatic Cancer | Adenocarcinoma | BxPC-3 | NA | FACs followed by SFA | NA | 0.48 | 0.456 | 27999190 |
| CD24 | 1645 | LTM | Pancreatic Cancer | Adenocarcinoma | BxPC-3 | NA | FACs followed by SP assay | NA | 0.48 | 0.456 | 22963768 |
| CD24 | 1645 | LTM | Pancreatic Cancer | Adenocarcinoma | BxPC-3 | NA | SFA followed by FACs | NA | 0.48 | 0.456 | 30853342 |
| CD24 | 1645 | LTM | Pancreatic Cancer | Adenocarcinoma | BxPC-3 | NA | SFA followed by FACs | NA | 0.48 | 0.456 | 29719602 |
| LIN28A | 15986 | LTM | Pancreatic Cancer | Adenocarcinoma | BxPC-3 | Gemcitabine | qRT-PCR and Western Blotting followed by SFA | NA | 0.48 | 0.0138 | 28703793 |
| MYC | 7553 | LTM | Pancreatic Cancer | Adenocarcinoma | BxPC-3 | NA | SFA followed by RT-PCR and Western Blotting | NA | 0.48 | 0.1304 | 24305593 |
| MYC | 7553 | LTM | Pancreatic Cancer | Adenocarcinoma | BxPC-3 | NA | SFA followed by qRT-PCR | NA | 0.48 | 0.1304 | 29048549 |
| NANOG | 20857 | LTM | Pancreatic Cancer | Adenocarcinoma | BxPC-3 | Gemcitabine | qRT-PCR and Western Blotting followed by SFA | NA | 0.48 | 0.5461 | 27576197 |
| NANOG | 20857 | LTM | Pancreatic Cancer | Adenocarcinoma | BxPC-3 | Gemcitabine | qRT-PCR and Western Blotting followed by SFA | NA | 0.48 | 0.5461 | 28703793 |
| NANOG | 20857 | LTM | Pancreatic Cancer | Adenocarcinoma | BxPC-3 | NA | FACs followed by Western Blotting | NA | 0.48 | 0.5461 | 31713003 |
| NANOG | 20857 | LTM | Pancreatic Cancer | Adenocarcinoma | BxPC-3 | NA | Western Blotting and SFA | NA | 0.48 | 0.5461 | 33082357 |
| NANOG | 20857 | LTM | Pancreatic Cancer | Adenocarcinoma | BxPC-3 | NA | SFA followed by Western Blotting | NA | 0.48 | 0.5461 | 32766132 |
| NANOG | 20857 | LTM | Pancreatic Cancer | Adenocarcinoma | BxPC-3 | NA | Western Blotting | NA | 0.48 | 0.5461 | 29970519 |
| NANOG | 20857 | LTM | Pancreatic Cancer | Adenocarcinoma | BxPC-3 | NA | SFA followed by qRT-PCR | NA | 0.48 | 0.5461 | 29048549 |
| NANOG | 20857 | LTM | Pancreatic Cancer | Adenocarcinoma | BxPC-3 | Gemcitabine | FACs | NA | 0.48 | 0.5461 | 31713003 |
| POU5F1 | 9221 | LTM | Pancreatic Cancer | Adenocarcinoma | BxPC-3 | Gemcitabine | qRT-PCR and Western Blotting followed by SFA | NA | 0.48 | 0.6448 | 28703793 |
| POU5F1 | 9221 | LTM | Pancreatic Cancer | Adenocarcinoma | BxPC-3 | NA | SFA followed by RT-PCR and Western Blotting | NA | 0.48 | 0.6448 | 24305593 |
| POU5F1 | 9221 | LTM | Pancreatic Cancer | Adenocarcinoma | BxPC-3 | NA | FACs followed by Western Blotting | NA | 0.48 | 0.6448 | 31713003 |
| POU5F1 | 9221 | LTM | Pancreatic Cancer | Adenocarcinoma | BxPC-3 | NA | Western Blotting and SFA | NA | 0.48 | 0.6448 | 33082357 |
| POU5F1 | 9221 | LTM | Pancreatic Cancer | Adenocarcinoma | BxPC-3 | NA | SFA followed by Western Blotting | NA | 0.48 | 0.6448 | 30853342 |
| POU5F1 | 9221 | LTM | Pancreatic Cancer | Adenocarcinoma | BxPC-3 | NA | SFA followed by Western Blotting | NA | 0.48 | 0.6448 | 32766132 |
| POU5F1 | 9221 | LTM | Pancreatic Cancer | Adenocarcinoma | BxPC-3 | NA | SFA followed by qRT-PCR | NA | 0.48 | 0.6448 | 29048549 |
| POU5F1 | 9221 | LTM | Pancreatic Cancer | Adenocarcinoma | BxPC-3 | Gemcitabine | FACs | NA | 0.48 | 0.6448 | 31713003 |
| POU5F1 | 9221 | LTM | Pancreatic Cancer | Adenocarcinoma | BxPC-3 | NA | FACs followed by SP assay | NA | 0.48 | 0.6448 | 22963768 |
| POU5F1 | 9221 | LTM | Pancreatic Cancer | Adenocarcinoma | BxPC-3 | NA | SFA followed by FACs | NA | 0.48 | 0.6448 | 29719602 |
| PROM1 | 9454 | LTM | Pancreatic Cancer | Adenocarcinoma | BxPC-3 | NA | SFA followed by RT-PCR and Western Blotting | NA | 0.48 | 0.7582 | 30802827 |
| PROM1 | 9454 | LTM | Pancreatic Cancer | Adenocarcinoma | BxPC-3 | NA | SFA followed by RT-PCR and Western Blotting | NA | 0.48 | 0.7582 | 30802827 |
| PROM1 | 9454 | LTM | Pancreatic Cancer | Adenocarcinoma | BxPC-3 | NA | SFA followed by IF staining | NA | 0.48 | 0.7582 | 26709750 |
| PROM1 | 9454 | LTM | Pancreatic Cancer | Adenocarcinoma | BxPC-3 | NA | qRT-PCR | NA | 0.48 | 0.7582 | 26035122 |
| PROM1 | 9454 | LTM | Pancreatic Cancer | Adenocarcinoma | BxPC-3 | NA | SFA followed by qRT-PCR | NA | 0.48 | 0.7582 | 29048549 |
| PROM1 | 9454 | LTM | Pancreatic Cancer | Adenocarcinoma | BxPC-3 | NA | FACs and SFA | NA | 0.48 | 0.7582 | 33537082 |
| PROM1 | 9454 | LTM | Pancreatic Cancer | Adenocarcinoma | BxPC-3 | Gemcitabine | FACs | NA | 0.48 | 0.7582 | 31713003 |
| PROM1 | 9454 | LTM | Pancreatic Cancer | Adenocarcinoma | BxPC-3 | NA | FACs | NA | 0.48 | 0.7582 | 31713003 |
| PROM1 | 9454 | LTM | Pancreatic Cancer | Adenocarcinoma | BxPC-3 | NA | FACs | NA | 0.48 | 0.7582 | 31856088 |
| PROM1 | 9454 | LTM | Pancreatic Cancer | Adenocarcinoma | BxPC-3 | Gemcitabine | FACs followed by SFA | NA | 0.48 | 0.7582 | 27576197 |
| PROM1 | 9454 | LTM | Pancreatic Cancer | Adenocarcinoma | BxPC-3 | NA | FACs followed by Tumorigenicity assay | NA | 0.48 | 0.7582 | 23338123 |
| PROM1 | 9454 | LTM | Pancreatic Cancer | Adenocarcinoma | BxPC-3 | NA | SFA followed by FACs | NA | 0.48 | 0.7582 | 24305593 |
| PROM1 | 9454 | LTM | Pancreatic Cancer | Adenocarcinoma | BxPC-3 | NA | SFA followed by FACs | NA | 0.48 | 0.7582 | 30853342 |
| SOX2 | 11195 | LTM | Pancreatic Cancer | Adenocarcinoma | BxPC-3 | Gemcitabine | qRT-PCR and Western Blotting followed by SFA | NA | 0.48 | 0.5695 | 27576197 |
| SOX2 | 11195 | LTM | Pancreatic Cancer | Adenocarcinoma | BxPC-3 | Gemcitabine | qRT-PCR and Western Blotting followed by SFA | NA | 0.48 | 0.5695 | 28703793 |
| SOX2 | 11195 | LTM | Pancreatic Cancer | Adenocarcinoma | BxPC-3 | NA | FACs followed by Western Blotting | NA | 0.48 | 0.5695 | 31713003 |
| SOX2 | 11195 | LTM | Pancreatic Cancer | Adenocarcinoma | BxPC-3 | NA | Western Blotting and SFA | NA | 0.48 | 0.5695 | 33082357 |
| SOX2 | 11195 | LTM | Pancreatic Cancer | Adenocarcinoma | BxPC-3 | NA | SFA followed by Western Blotting | NA | 0.48 | 0.5695 | 30853342 |
| SOX2 | 11195 | LTM | Pancreatic Cancer | Adenocarcinoma | BxPC-3 | NA | SFA followed by Western Blotting | NA | 0.48 | 0.5695 | 32766132 |
| SOX2 | 11195 | LTM | Pancreatic Cancer | Adenocarcinoma | BxPC-3 | NA | Western Blotting | NA | 0.48 | 0.5695 | 29970519 |
| SOX2 | 11195 | LTM | Pancreatic Cancer | Adenocarcinoma | BxPC-3 | Gemcitabine | FACs | NA | 0.48 | 0.5695 | 31713003 |
| SOX2 | 11195 | LTM | Pancreatic Cancer | Adenocarcinoma | BxPC-3 | NA | FACs followed by SP assay | NA | 0.48 | 0.5695 | 22963768 |
| SOX2 | 11195 | LTM | Pancreatic Cancer | Adenocarcinoma | BxPC-3 | NA | SFA followed by FACs | NA | 0.48 | 0.5695 | 29719602 |
| ABCB1 | 40 | LTM | Pancreatic Cancer | Adenocarcinoma | BxPC-3 | NA | SFA followed by Western Blotting | NA | 0.28 | 0.0604 | 30853342 |
| ABCB1 | 40 | LTM | Pancreatic Cancer | Adenocarcinoma | BxPC-3 | NA | SFA followed by qRT-PCR | NA | 0.28 | 0.0604 | 29048549 |
| ABCG2 | 74 | LTM | Pancreatic Cancer | Adenocarcinoma | BxPC-3 | NA | SFA followed by Western Blotting | NA | 0.28 | 0.1739 | 30853342 |
| STAT3 | 11364 | LTM | Pancreatic Cancer | Adenocarcinoma | BxPC-3 | NA | SFA and Western Blotting | NA | 0.28 | 0.0223 | 27748818 |
| STAT3 | 11364 | LTM | Pancreatic Cancer | Adenocarcinoma | BxPC-3 | Gemcitabine | Western Blotting followed by SFA | NA | 0.28 | 0.0223 | 27576197 |
| NES | 7756 | LTM | Pancreatic Cancer | Adenocarcinoma | BxPC-3 | NA | SFA followed by IF staining | NA | 0.24 | 0.0573 | 26709750 |
| MET | 7029 | LTM | Pancreatic Cancer | Adenocarcinoma | BxPC-3 | NA | qRT-PCR | NA | 0.2 | 0.0191 | 26035122 |
| FLOT2 | 3758 | LTM | Pancreatic Cancer | Adenocarcinoma | BxPC-3 | NA | FACs | NA | 0.12 | 0.0032 | 31856088 |
| MS4A1 | 7315 | LTM | Pancreatic Cancer | Adenocarcinoma | BxPC-3 | NA | FACs followed by SP assay | NA | 0.12 | 0.0085 | 22963768 |